Avalon GloboCare Corp, a leading global developer of cell-based technologies and therapeutics, announced today that Weill Cornell Medicine has selected its subsidiary Genexosome Technologies’ proprietary...
Read More »Avalon GloboCare Corp, a leading global developer of cell-based technologies and therapeutics, announced today that Weill Cornell Medicine has selected its subsidiary Genexosome Technologies’ proprietary...
Read More »